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Background: Key goals in the treatment of CAP include early response to treatment and achievement of clinical
stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials
for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical
Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the
Hospital Setting) was a retrospective observational study, providing current data on the clinical management and
resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes
of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as assessed by Halm’s
criteria) compared with patients with later positive response (TCS >4 days).
Methods: Patients were adults, hospitalized with CAP (2010–2011) and requiring in-hospital treatment with
intravenous antibiotics.
Results: Of the 2039 patients included in REACH, 585 (28.7%) had TCS assessed by Halm’s criteria: 332 (56.8%) showed
early response (median 3.0 days), and 253 (43.2%) showed later response to treatment (median 7.0 days). Use of Halm’s
criteria varied across participating countries, ranging from 0% (Belgium) to 49.1% (UK). Patient characteristics and
relevant medical history were similar between the two groups. There were no notable differences in initial antibiotic
therapy between groups, except that more early responders had been treated with amoxicillin–clavulanate
and amoxicillin monotherapy (22.6%; 7.5%, respectively) than later responders (5.9%; 1.2%, respectively). Initial
treatment modification and re-infection or recurrences were less frequent in early responders compared with
later responders (14.2% and 3.3% vs. 34.8% and 5.9%, respectively). Early responders had a shorter duration of
hospitalization (mean 9.4 ± SD 7.0; median 8.0 days vs. mean 15.6 ± SD 10.5; median 12.0 days, respectively), lower
rate of ICU admission (3.3% vs. 21.3%) and shorter duration of ICU stay (mean 6.2 ± SD 5.7; median 4.0 days vs. mean
10.4 ± SD 10.1; median 8.0 days, respectively) compared with later responders. Mortality was low in both groups.
Conclusions: Achieving early clinical stabilization in CAP (≤4 days) is associated with improved outcomes, lower
requirement for initial treatment modification or readmission and lower resource use, compared with a later response.
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In Europe, the clinical and economic burden of commu-
nity-acquired pneumonia (CAP) remains high [1], and
hospitalization for CAP is responsible for up to 80% of
the total costs of this disease [2]. REACH (REtrospective
Study to Assess the Clinical Management of Patients With
Moderate-to-Severe Complicated Skin and Soft Tissue
Infections [cSSTI] or CAP in the Hospital Setting) was
a retrospective, observational study undertaken in 128
centres in 10 European countries, funded by AstraZeneca,
and designed to provide current data on the clinical
management and resource burden of CAP in real-life
settings in hospitals [3]. The data obtained from this
study reveal a large heterogeneity in clinical management
patterns. Initial antibiotic treatment modification, for any
reason, occurred in around one-third of affected patients
and was more common in patients with comorbidities
than in those without. Rates of initial antibiotic treatment
modification and associated outcomes, such as overall
mortality, were increased in patients with more compli-
cated or more severe illness and were associated with
considerable additional resource use, particularly length
of hospital stay (Ostermann et al., REACH CAP health
economics publication). A number of other factors in-
fluence patient outcomes in CAP, such as the decision
whether to hospitalize [4,5], as patients with low-risk
disease fare better with outpatient treatment [5] and
the greatest proportion of pneumonia-related mortality
and healthcare expenditure occurs among those persons
who are hospitalized [5-7]. This decision is often based
on severity assessment and the presence of risk factors
associated with severe CAP, including age (≥ 65 years),
nursing home residence and comorbidities such as
congestive heart failure, chronic renal failure and dia-
betes mellitus [1,8-10], and recurrent infections may
affect outcomes. There is often difficulty in obtaining
a microbiological diagnosis and the pathogen is not
identified in a high proportion (35–67%) of cases, resulting
in empiric rather than targeted antibacterial treatment
[11,12]. Early failure of treatment (within 48–72 hours)
is associated with high morbidity and mortality rates
and most cases occur because of inadequate response
[13]. The monitoring of response to treatment, as rec-
ommended by The European Respiratory Society (ERS),
in collaboration with The European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) by simple
clinical criteria, including body temperature, respiratory
and haemodynamic parameters, is therefore essential [4].
In clinical practice, clinical stability is acknowledged as
a guide to when antibiotic therapy may be switched from
intravenous (IV) to oral. Thus, the recognition of clinical
stability is important as an outcome for treatment of CAP.
The guidelines on the management of CAP published by
the American Thoracic Society (ATS) and the InfectiousDiseases Society of America (IDSA) [5] give a definition of
clinical stability that is based on objective parameters and
developed from those described by Halm et al. [14]. These
criteria were developed as a specific and objective measure
for clinical stability in CAP and are consistent with,
and similar to, recent US Food and Drug Administration
(FDA) recommendations for early response endpoints
(72 hours after initiation of treatment) in non-inferiority
clinical trials for the treatment of community-acquired
bacterial pneumonia [15]. This recommendation resulted
from a consultation of the Anti-Infective Drugs Advisory
Committee and was largely based on historical data [15].
This endpoint may be more clinically relevant, as an early
indication of treatment failure can allow the selection of
an alternative antimicrobial therapy and avoid prolonged
use of inappropriate treatment, which may impact clinical
outcomes and lower healthcare resource utilization.
The purpose of this subanalysis of the REACH study
was to analyse the characteristics of patients showing
an early response to treatment (time to clinical stability
[TCS] ≤ 4 days) compared with patients with later response
(TCS > 4 days) and to identify any impact on associated
outcomes.
Methods
REACH was a multinational, multicentre, observational,
retrospective cohort study of patients hospitalized with
CAP (NCT01293435). A total of 2,039 patients, aged 18
years or older, hospitalized and treated with IV antibiotics
were enrolled in 128 sites in 10 participating countries
(Belgium, France, Germany, Greece, Italy, the Netherlands,
Portugal, Spain, Turkey and the UK). The study was
performed according to Good Clinical Practice and the
Declaration of Helsinki. All local ethics committees ap-
proved the study protocol. Local legislation relating to
written informed consent for non-interventional studies
was followed in each country; in Germany and Portugal,
where this information is mandatory, written informed
consent was collected. The list of ethics committees and
health authorities that approved the study is available
to the public at: www.astrazenecaclinicaltrials.com. All
patients included in the analysis were hospitalized between
March 2010 and February 2011. Study design and patient
inclusion and exclusion criteria are summarized in the
REACH primary publication [3]. In brief, the study
collected data regarding patient demographics, disease
characteristics and diagnosis, management, clinical out-
comes (including modification of initial antibiotic treat-
ment for any reason and TCS) and healthcare resource
use, via an electronic Case Report Form (eCRF) completed
by the investigator at each site.
‘Initial antibiotic treatment modification’ was defined as
a change in initial antibiotic treatment due to insufficient
response, adverse reaction, interaction with other drugs,
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of microbiological tests, or changes to or additions of new
agents in a subsequent line (alone or in combination).
The eCRF also allowed a response of ‘other’ or ‘unknown’.
Several antibiotic treatment modifications in the same
patient were counted as a single case. Changes in dose
or frequency of an existing antibiotic (considered as dose
escalation or adaptation), removal of an antibiotic from a
combination and adaptation of the dose or frequency of
the remaining antibiotic, were not considered as treatment
modification. TCS was recorded on the eCRF in response
to the question ‘What was the time to clinical stability?’
Available options were ‘based on the Halm criteria for
clinical stability’ (specifically, the first day that the fol-
lowing clinical variables are stable: systolic blood pres-
sure ≥ 90 mm Hg; heart rate ≤ 100 beats/min; respiratory
rate ≤ 24; temperature ≤ 38.3°C; oxygen saturation ≥ 90%;
ability to eat; normal mental function) [14]. Alternative
options were ‘based on the change from IV to oral ther-
apy’, ‘based on other criteria’ and ‘other’.
This descriptive analysis focuses on the characteristics,
antibiotic treatments, clinical outcomes and use of health-
care resources of those patients from the REACH study
whose achievement of clinical stability was assessed
according to Halm’s criteria [14]. Characteristics of pa-
tients showing an early response to treatment (defined as
a TCS ≤ 4 days) were compared with those of patientsTable 1 Patient demographics
Characteristic, n (%) Early respo
n = 33
Age, years, mean (SD) [median] 63.8 (19.0)
≥ 65 years 187 (55.
Sex, male 204 (61.
Ethnic origin
White 225 (67.
Non-white 8 (2.4)
Unknown/missing 9 (2.7)
Not applicable* 90 (27.1
Previous admission to hospital with CAP (last 3 months) 8 (2.4)
Haemodialysis 0
Chemotherapy for active cancer 1 (0.3)
Smoking status†
Non-smoker 129 (38.
Ex-smoker 94 (28.1
Occasional smoker 2 (0.6)
Habitual smoker 89 (26.8
Unknown 18 (5.4
*All patients in this category were from France, where this question is not permitte
†Definitions: Never smoked: patients who have never smoked > 20 g of tobacco in
Occasional smoker: patients who smoke < 1 tobacco product per day; Habitual smo
SD = standard deviation; TCS = time to clinical stability.with a later response (TCS > 4 days), and corresponding
outcomes and resource use were measured. A further
analysis was conducted of patients who died in both
the early and late responders groups.
Results
Use of Halm’s criteria for the assessment of clinical
stability in the participating countries
Of the 2039 patients included in the REACH study, 585
(28.7%) patients had TCS assessed by Halm’s criteria [14],
as noted on the eCRF. The use of Halm’s criteria was vari-
able across the different participating countries; Belgium
(n = 0/191; 0%); France (n = 122/366; 33.3%); Germany
(n = 7/50; 14%); Greece (n = 71/215; 33.0%); Italy (n = 91/
300; 30.3%); the Netherlands (n = 39/203; 19.2%); Portugal
(n = 13/121; 10.7%); Spain (n = 131/279; 47.0%); Turkey
(n = 55/200; 27.5%) and UK (n = 56/114; 49.1%).
Patient population
Of the 585 patients who had TCS assessed by Halm’s cri-
teria [14], 332 (56.8%) showed early response (≤ 4 days;
median 3.0 days) and 253 (43.2%) showed later response
to treatment (> 4 days; median 7.0 days). Patient demo-
graphics were similar between the two groups, although
some numerical differences were observed (Table 1).
Disease characteristics and triggering symptoms are shown
in Table 2. Patients without comorbidities tended to benders
2
Later responders
n = 253
Patients without Halm-based
assessment of TCS n = 1454
[68] 64.5 (18.2) [69] 64.7 (18.5) [68]
8) 137 (54.2) 827 (56.9)
4) 144 (56.9) 848 (58.3)
8) 217 (85.8) 1131 (77.8)
3 (1.2) 40 (2.8)
3 (1.2) 39 (2.7)
) 30 (11.9) 244 (16.8)
9 (3.6) 82 (5.6)
1 (0.4) 5 (0.3)
1 (0.4) 28 (1.9)
5) 108 (42.7) 467 (32.1)
) 79 (31.2) 380 (26.1)
2 (0.8) 38 (2.6)
) 46 (18.2) 328 (22.6)
) 18 (7.1) 241 (16.6)
d in clinical studies.
their lifetime; Ex-smoker: patients who stopped smoking ≥ 365 days ago:
ker: patients who smoke ≥ 1 tobacco products/day.
Table 2 Medical history and disease characteristics
Characteristic Early responders
n = 332
Later responders
n = 253
Patients without Halm-based
assessment of TCS n = 1454
Relevant medical conditions at hospitalization (initial visit*)
(≥ 5% of analysis population), n (%)
Any relevant condition 255 (76.8) 210 (83.0) 1133 (77.9)
Respiratory disease 108 (32.5) 90 (35.6) 491 (33.8)
Diabetes 54 (16.3) 52 (20.6) 263 (18.1)
Congestive heart disease 48 (14.5) 51 (20.2) 237 (16.3)
Cancer/malignancy 30 (9.0) 27 (10.7) 180 (12.4)
Peripheral vascular disease 34 (10.2) 23 (9.1) 126 (8.7)
Renal disease 17 (5.1) 20 (7.9) 110 (7.6)
Other relevant conditions† 118 (35.5) 102 (40.3) 464 (31.9)
Age of patients with comorbidities, years, mean (SD) [median] 67.5 (17.2) [71] 66.3 (17.92) [72] 68.2 (16.4) [71]
Age of patients without comorbidities, years, mean (SD) [median] 51.9 (19.7) [49] 55.5 (17.0) [54] 52.4 (20.1) [50]
Medication history in the 3 months prior to hospitalization, n (%)
Any prior medication 159 (47.5) 148 (58.5) 836 (57.5)
Antibiotics/antivirals 51 (15.4) 52 (20.6) 292 (20.1)
Anticoagulants 56 (16.9) 39 (15.4) 206 (14.2)
Immunosuppressants/immunomodulators 19 (5.7) 19 (7.5) 113 (7.8)
Non-steroidal anti-inflammatory drugs 23 (6.9) 16 (6.3) 98 (6.7)
Any other relevant therapies* 58 (17.5) 47 (18.6) 274 (18.8)
Unknown 8 (2.4) 18 (7.1) 120 (8.3)
*Visit to hospital for current infection or date of diagnosis of infection for patients already hospitalized.
†As defined by the investigator.
SD = standard deviation; TCS = time to clinical stability.
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vs. 51.9 years in the early responders group). Fewer of
the early responders had comorbidities compared with
the later responders (respiratory disease 32.5% vs. 35.6%;
diabetes 16.3% vs. 20.6%; congestive heart disease 14.5%
vs. 20.2%, respectively) (Table 2). Disease severity, deter-
mined by PORT/PSI (Pneumonia Outcomes Research
Team/Pneumonia Severity Index) [4,16] or CURB-65
(Confusion, Urea nitrogen, Respiratory rate, Blood pres-
sure, ≥ 65 years of age) [4] scores, indicates that later
responders tended to have more severe disease (PORT/
PSI class V) compared with early responders (18.2% vs.
7.7% of patients with a PORT/PSI score, respectively).
Interestingly, numerically more later responders had a
PORT/PSI or CURB-65 score recorded than patients
with an early response (30.4% vs. 19.6%; 46.6% vs. 38.9%,
respectively) (Table 3).
Diagnostic information
All patients underwent a microbiological test, the majority
having sputum examination (39.5% early responders and
47.0% later responders) and/or blood culture (49.4%
early responders and 60.1% later responders). Negative
cultures were more frequent in early (74.7%) than in
later responders (66.0%) (Table 4). In the patients witha microbiologically confirmed infection (n = 87 in both
groups), early responders were less frequently infected with
‘difficult-to-treat’ microorganisms, such as Pseudomonas
aeruginosa (4.6%), or had aspiration pneumonia (1.1%),
compared with later responders (9.2% and 4.6%, respect-
ively). There was a single case of methicillin-resistant
Staphylococcus aureus detected in a later-responder. Other
microorganisms were found in similar proportions in both
subpopulations.
Outcomes and resource use
No notable differences in first-line antibiotic therapy were
seen between groups, except that amoxicillin–clavulanate
or amoxicillin monotherapy as initial therapy was more
commonly used in early responders (22.6% and 7.5%,
respectively) than later responders (5.9% and 1.2%, respect-
ively) (Table 5).
The most notable difference in outcomes was that early
responders had a lower requirement for initial antibiotic
treatment modification (14.2%) than patients with a later
response (34.8%). Readmission to hospital after discharge
was also less frequently observed in early responders than
in later responders (Table 6).
An association between early response and shorter
duration of hospitalization (mean 9.4; standard deviation
Table 3 Characteristics of index community-acquired pneumonia infection
Characteristic, n (%) Early responders
n = 332
Later responders
n = 253
Patients without Halm-based
assessment of TCS n = 1454
Type of CAP
CAP* 279 (84.0) 210 (83.0) 1118 (76.9)
HCAP† 24 (7.2) 20 (7.9) 201 (13.8)
Immunocompromised/immunosuppressed 8 (2.4) 11 (4.3) 53 (3.6)
Other 0 2 (0.6) 37 (2.5)
Unknown 21 (6.3) 10 (4.0) 54 (3.7)
Radiographic findings suggestive of bacterial pneumonia
Infiltrate 175 (52.7) 113 (44.7) 880 (60.5)
Consolidation 183 (55.1) 167 (66.0) 597 (41.1)
Pleural effusion 40 (12.0) 44 (17.4) 235 (16.2)
Other 19 (5.7) 14 (5.5) 67 (4.6)
Unknown 0 1 (0.4) 15 (1.0)
Signs of acute illness at diagnosis
New or increased cough 258 (77.7) 202 (79.8) 1115 (76.7)
Purulent sputum or change in sputum character 182 (54.8) 127 (50.2) 744 (51.2)
Auscultatory findings consistent with pneumonia 253 (76.2) 184 (72.7) 1055 (72.6)
Dyspnoea, tachypnoea or hypoxaemia 256 (77.1) 210 (83.0) 1025 (70.5)
Fever or hypothermia 213 (64.2) 153 (60.5) 951 (65.4)
White blood cell count > 10000 cells/mm3 or < 4500 cells/mm3 210 (63.3) 179 (70.8) 963 (66.2)
Prognosis based on severity indices
PORT/PSI 65 (19.6) 77 (30.4) 212 (14.6)
I/II‡ 17 (26.2) 13 (16.9) 41 (19.3)
III/IV 43 (66.2) 50 (64.9) 138 (65.1)
V 5 (7.7) 14 (18.2) 33 (15.6)
CURB-65 129 (38.9) 118 (46.6) 280 (19.3)
0-1‡ 49 (38.0) 23 (19.5) 82 (29.3)
2 38 (29.5) 42 (35.6) 105 (37.5)
3 16 (12.4) 23 (19.5) 61 (21.8)
4 21 (16.3) 26 (22.0) 21 (7.5)
5 2 (1.6) 3 (2.5) 3 (1.1)
Unknown 3 (2.3) 1 (0.8) 8 (2.9)
*Residence in private house or apartment only.
†Responses considered HCAP were all other residential statuses, with the exception of immunocompromised/immunosuppressed.
‡The proportions are calculated with respect to the total number of patients in which this score was reported to have been used to assess clinical stability.
CAP = community-acquired pneumonia; CURB-65 = Confusion, Urea nitrogen, Respiratory rate, Blood pressure, ≥ 65 years of age; HCAP = healthcare-associated
pneumonia; PORT/PSI = Pneumonia Outcomes Research Team/Pneumonia Severity Index; SD = standard deviation; TCS = time to clinical stability.
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intensive care unit (ICU; 3.3%) and shorter duration of
ICU stay (mean 6.2; SD: 5.7; median 4.0 days) was observed
compared with later responders (mean 15.6; SD: 10.5;
median 12.0 days; 21.3%; mean 10.4; SD: 10.1; median
8.0 days, respectively).
Hospital resource use, such as blood pressure support,
mechanical ventilation and parenteral nutrition, was
higher in patients who had a later response, and there
were more cases of septic shock compared with patientswith an early response (7.9% vs. 0.3%) (Table 6). There
were few deaths reported (n = 6). Reasons for death in
early responders (n = 2) were CAP-related in one case,
and non-CAP-related in the other, based on investigator
assessment. Death in later responders (n = 4) was related
to CAP in two cases, unrelated in one and unknown in
the fourth. “Post-clinical stability”, differences between
early and later responders in terms of length of stay and
ICU admissions were minimal (mean length of hospital
stay 5.9 days, both early and later responders (Table 6).
Table 4 Microbiological diagnosis
Microbiological diagnosis, n [patients with
a positive microbiological diagnosis] (%)
Early responders
n = 332
Later responders
n = 253
Patients without Halm-based
assessment of TCS n = 1454
Number of patients with a microbiological diagnosis 87 (26.2) 87 (34.4) 408 (28.1)
Gram-positive cocci* 40 (46.0) 38 (43.7) 208 (51.0)
Streptococcus pneumoniae 32 (36.8) 28 (32.2) 168 (41.2)
Penicillin-resistant Streptococcus pneumoniae 0 1 (1.1) 1 (0.2)
Methicillin-resistant Staphylococcus aureus 0 1 (1.1) 11 (2.7)
Methicillin-susceptible Staphylococcus aureus 9 (10.3) 9 (10.3) 33 (8.1)
Legionella spp. 4 (4.6) 3 (3.4) 13 (3.2)
Mycoplasma pneumoniae 4 (4.6) 1 (1.1) 13 (3.2)
Chlamydophila pneumoniae 0 2 (2.3) 11 (2.7)
Gram-negative bacilli† 15 (17.2) 11 (12.6) 81 (19.8)
Haemophilus influenzae 7 (8.0) 3 (3.4) 23 (5.6)
Haemophilus parainfluenzae 3 (3.4) 1 (1.1) 2 (0.5)
Moraxella catarrhalis 2 (2.3) 0 7 (1.7)
Pseudomonas aeruginosa 4 (4.6) 8 (9.2) 29 (7.1)
Escherichia coli 4 (4.6) 3 (1.4) 29 (7.1)
Klebsiella spp. 2 (2.3) 0 17 (4.2)
Aspiration pneumonia§ 1 (1.1) 4 (4.6) 12 (2.9)
Other microorganisms 19 (21.8) 32 (36.8) 82 (20.1)
Unknown (not identified) 248 (74.7) 167 (66.0) 1060 (72.9)
*Includes other Streptococcus spp. and Staphylococcus spp.
†Includes Morganella morganii, Pasteurella multocida, Proteus mirabilis and Serratia marcescens, Acinetobacter spp. and Hafnia alvei.
§Commonly applied to situations when a patient with risk factors for aspiration presents with pneumonia.
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tients who did not have TCS assessed by Halm’s criteria
revealed no relevant differences in the baseline data,
apart from a small difference in the proportion of
patients with healthcare-associated pneumonia (HCAP)
(13.8% vs. 7.2% of early responders and 7.9% of later
responders). In addition, a smaller proportion of patients
had PORT/PSI or CURB-65 assessment of disease severity
(Table 3). Clinical outcomes and resource use were also
similar, except for a higher mortality rate observed in
patients not assessed by Halm’s criteria (9.7% vs. 0.6%
for early responders and 1.6% for later responders)
(Table 6).
An analysis of those patients who had received antibiotic
pre-treatment, compared with those who had not, showed
that pre-treatment with antibiotics was associated with
a shorter hospital length of stay for both early and later
responders (mean 8.6 vs. 10.1 days for early responders
and 15.3 vs. 17.0 days for later responders) (Table 7).
Fewer later responders with antibiotic pre-treatment
were admitted to ICU, and those that were, remained
there for a shorter duration than patients without anti-
biotic pre-treatment. A higher mortality rate was ob-
served in late responders with antibiotic pre-treatment
compared with those without pre-treatment (5.2% vs.
0.5%) (Table 7).Discussion
The characteristics, clinical outcomes and hospital resource
use of patients included in the REACH study were analysed
according to their TCS using Halm’s criteria. Achieving
early clinical stabilization (≤ 4 days) in patients with
CAP appears to be associated with shorter hospital
length of stay, lower incidence of admission to ICU or
readmission to hospital for the same infection, and
lower resource use compared with patients with a later
response. The results presented here highlight how
early identification of patients with a higher risk of a
later response to treatment could assist the clinician in
improving the chance of an early response by careful
microbial stewardship, more aggressive treatment, early
initiation of antibiotics and closer monitoring of response
in these patients of concern.
Patients showing early or later response to treatment
were similar in terms of demographics; however, there
was a numerical tendency for those with a later response
to have more comorbidity, or to have been in receipt of
prior medication, in particular antivirals or antibiotics,
in the 3 months prior to hospitalization. Data obtained
from patients who were assessed for severity of disease
with either the PORT/PSI or CURB-65 scoring systems
suggest that patients with a later response had more
severe disease than early responders. Intuitively it might
Table 5 Antibiotic therapies
Antibiotic, n (%) Early responders
n = 332
Later responders
n = 253
Combinations
Penicillin or penicillin + β-
lactamase inhibitor + macrolide
50 (15.1) 22 (8.7)
Cephalosporin (except
cefuroxime) +macrolide
33 (9.9) 48 (19.0)
Cephalosporin (except
cefuroxime) + fluoroquinolone
25 (7.5) 34 (13.4)
Penicillin or penicillin–β-
lactamase + fluoroquinolone
16 (4.8) 17 (6.7)
Monotherapies
Amoxicillin–clavulanate 75 (22.6) 15 (5.9)
Amoxicillin 25 (7.5) 3 (1.2)
Ceftriaxone 25 (7.5) 16 (6.3)
Levofloxacin 22 (6.6) 16 (6.3)
Moxifloxacin 15 (4.5) 10 (4.0)
Ampicillin–sulbactam 5 (1.5) 3 (1.2)
Piperacillin–tazobactam 4 (1.2) 7 (2.8)
Azithromycin 4 (1.2) 3 (1.2)
Clarithromycin 3 (0.9) 3 (1.2)
Cefuroxime 3 (0.9) 2 (0.8)
Meropenem 1 (0.3) 2 (0.8)
Ciprofloxacin 0 2 (0.8)
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reach clinical stability later, and might require more
aggressive treatment and closer follow-up, compared
with patients who responded early to treatment. More
patients with a later response had severity scores recorded
than those with an early response. Moreover, use of sever-
ity scoring was variable or even absent in some countries
(e.g. Belgium) and in those that did use a scoring system,
PORT/PSI in particular, there was a trend to more pa-
tients being classed as moderate (III/IV) or high (V),
which may suggest that physicians tend to score those
patients with more severe disease.
The limitations associated with the retrospective design
of this study, and the consequent unavailability of some
values, have been discussed previously [3]. Significant
heterogeneity in the use of Halm’s criteria for the
assessment of clinical stability across the participating
countries, ranging from 0% in Belgium, where TCS was
not assessed using the Halm criteria in any patient, to
49.1% in the UK, and averaging only 28.7% overall, is in
itself an important observation but highlights a limitation
of this subanalysis. A higher mortality rate was observed
in patients not assessed by Halm’s criteria. This may be
because this sub-population had more severe disease
according to the PORT/PSI and CURB-65 indices, but it is
also possible that the use of Halm’s criteria indicatesadherence to guidelines, and thus its use might be a
surrogate of quality of healthcare.
Patients in both groups were treated largely following
current ERS/ESCMID guidelines: aminopenicillin ± β-lac-
tamase inhibitor ±macrolide; levofloxacin or moxifloxacin
[4]. The observation that more early responders had been
treated with amoxicillin–clavulanate monotherapy than
later responders may be an indication that this treatment
is recommended in local hospital guidelines for the treat-
ment of CAP. In a recent study of treatment failure in
patients hospitalized with CAP in Switzerland, it was
found that those patients who had been treated initially
with moxifloxacin or a β-lactam plus macrolide combin-
ation experienced lower treatment failure rates and
reduced hospital stay, and thus reduced treatment costs,
compared with patients receiving β-lactam monotherapy
or a non-standardized antibiotic therapy [17].
Aliberti et al. [18] found that the interaction between
host characteristics (immune status and comorbidities),
pathogen characteristics (virulence, susceptibility and
resistance to antibiotics) and antibiotic characteristics
(timing, adequacy of therapy and pharmacokinetic factors)
determines the time in which a patient reached clinical
stability, and that the duration of IV therapy was, in
most cases, found to be tailored to the patient’s clinical
response. REACH was a retrospective observational study;
thus, physicians were not required to report the decision-
making process in the treatment of individual patients.
However, the data obtained do illustrate the importance
of identifying those patients of increased concern or at
higher risk of being a later responder to treatment, such as
patients with comorbidities. The high number of patients
without a microbiological diagnosis indicates that treat-
ment is, of necessity, empiric, with the potential for treat-
ment failure, which impacts on clinical outcomes and
healthcare resource use [19]. However, an understanding
of the local epidemiology can inform the physician’s choice
of treatment.
The higher frequency of initial antibiotic treatment
modification due to insufficient response or treatment
failure seen in the later responders group, compared
with the early responders, may be explained by a higher
incidence of inappropriate or discordant choice of initial
antibiotic. It has been previously reported that the
incidence of failure in patients with CAP ranges from
6 to 24% and may reach 31% in patients with severe
CAP [13,20,21]. Factors most often associated with
early failure have been reported to be more severe pneu-
monia, Legionella pneumonia, Gram-negative pneumonia,
or mixed infections and discordant antimicrobial therapy
[13,22]. Adherence or non-adherence to guidelines has
been shown to be dependent on the hospital, and the
speciality and training status of the prescribing physicians,
and is thus an independent risk factor for treatment failure
Table 6 Clinical outcomes and hospital resource use
Outcome, n (%) Early responders
n = 332
Later responders
n = 253
Patients without Halm-based
assessment of TCS n = 1454
Antibiotic treatment modification while on initial
therapy (excluding streamlining*)
47 (14.2) 88 (34.8) 454 (31.2)
Time to clinical stability, days, mean (SD) [median] 2.6 (0.95) [3.0] 9.0 (6.53) [7.0] 5.7 (5.0) [5.0]
Length of stay†, days, mean (SD) [median] 9.4 (7.0) [8.0] (n = 309) 15.6 (10.5) [12.0] (n = 246) 12.6 (10.7) [10.0] (n = 1423)
Length of stay after achievement of clinical stability‡,
days, mean (SD) [median]
5.9 (7.1) [4.0] (n = 305) 5.9 (7.0) [3.0] (n = 231) N/A
Patients admitted to ICU 11 (3.3) 54 (21.3) 213 (14.6)
Time in ICU‡, days, mean (SD) [median] (n) 6.2 (5.7) [4.0] (n = 11) 10.4 (10.1) [8.0] (n = 53) 9.5 (12.4) [5.0]
Patients admitted to ICU after achievement of clinical stability 0 1 (0.4) N/A
Reinfection/recurrence§ 11 (3.3) 15 (5.9) 68 (4.7)
Home-based care after discharge 6 (1.8) 11 (4.3) 56 (3.9)
Blood pressure support during hospitalization
Fluid resuscitation 24 (7.2) 37 (14.6) 190 (13.1)
Vasopressors 2 (0.6) 17 (6.7) 82 (5.6)
Invasive procedures 1 (0.3) 3 (1.2) 26 (1.8)
Isolation required 28 (8.4) 24 (9.5) 102 (7.0)
Mechanical ventilation required during hospitalization 24 (7.2) 48 (19.0) 208 (14.3)
Invasive 12 (3.6) 28 (11.1) 99 (6.8)
Non-invasive 12 (3.6) 25 (9.9) 129 (8.9)
Parenteral nutrition 5 (1.5) 19 (7.5) 70 (4.8)
Duration of parenteral nutrition, days, mean (SD) [median] 6.0 (3.5) [5.0] (n = 5) 8.2 (5.1) [6.5] (n = 18) 9.5 (12.0) [5.0] (n = 65)
Acute renal failure necessitating renal replacement therapy 1 (0.3) 6 (2.4) 39 (2.7)
Duration of renal failure, days, mean (SD) [median] 2.0 (0) [2.0] (n = 1) 14.3 (16.0) [9.5] (n = 4) 5.7 (7.2) [3.0] (n = 32)
Septic shock during hospitalization 1 (0.3) 20 (7.9) 63 (4.3)
Mortality 2 (0.6) 4 (1.6) 141 (9.7)
Post-discharge mortality 0 0 0
*De-escalation of treatment to narrower-spectrum antibiotics upon patient improvement or confirmed microbiological diagnosis.
†Includes duration of all hospitalizations for patients with recurrences.
‡Does not include duration of all hospitalizations for patients with recurrences.
§Refers to patients hospitalized again (due to CAP) after initial discharge.
ICU = intensive care unit; N/A = not applicable; SD = standard deviation.
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http://respiratory-research.com/content/15/1/6and mortality [22]. Empiric treatment that follows guide-
lines is associated with earlier TCS, and non-adherence
may result in longer hospital length of stay and greater use
of resources [23]. Data from the REACH study confirm
that a longer TCS is associated with a longer length of
hospital stay, and increased resource use such as more
admissions to, and longer time in, ICU, mechanical
ventilation, parenteral nutrition, acute renal failure and
a higher incidence of home-based care after discharge,
compared with patients with an early response.
In addition, recent data in patients with CAP have
shown an association between a longer TCS and a sig-
nificantly higher rate of adverse outcomes within 30 days
of discharge compared with patients with a shorter
TCS, which, the authors suggest, may be due to patients
being discharged with a systemic inflammatory response[24]. In our study, later responders were found to have
higher levels of reinfection/recurrence, compared with
early responders. These observations reinforce the re-
quirement for patients with a later response to treatment
to receive closer clinical observation and management
and a shorter time for follow-up visit after discharge.
Our analysis of the effect of TCS on subsequent out-
comes is slightly limited since some variables were not,
or could not be, measured specifically before and after
clinical stability. However, data on the length of hos-
pitalization and on admissions to ICU after achievement
of clinical stability show relatively small differences
between early and later responders in this study and
suggest such differences are more evident when looking
at hospitalization as a whole and not at the post-clinical
stability phase alone. In a recent retrospective analysis
Table 7 Clinical outcomes and hospital resource use for patients with and without antibiotic pre-treatment
Outcome, n (%) Early responders n = 332 Later responders n = 253
Without antibiotic
pre-treatment n = 266
With antibiotic
pre-treatment n = 61
Without antibiotic
pre-treatment n = 184
With antibiotic
pre-treatment n = 58
Antibiotic treatment modification while on initial
therapy (excluding streamlining*)
38 (14.3) 7 (11.5) 66 (35.9) 20 (34.5)
Time to clinical stability, days, mean (SD) [median]
based on Halm's criteria
2.6 (1.0) [2.0] 2.8 (0.9) [3.0] 9.2 (7.0) [7.0] 8.5 (5.7) [7.0]
Length of stay†, days, mean (SD) [median] 10.1 (7.7) [8.0] 8.6 (4.5) [7.0] 17.0 (12.6) [13.0] 15.3 (9.9) [12.0]
Patients admitted to ICU 9 (3.4) 2 (3.3) 44 (23.9) 9 (15.5)
Time in ICU‡, days mean (SD) [median] (n) 6.3 (6.3) [4.0] (n = 9) 5.5 (2.1) [5.5] (n = 2) 10.8 (10.9) [8.0] (n = 44) 8.9 (4.3) [9.0] (n = 8)
Reinfection/recurrence§ 9 (3.4) 2 (3.3) 10 (5.4) 5 (8.6)
Home-based care after discharge 6 (2.3) 0 9 (4.9) 2 (3.4)
Blood pressure support during hospitalization
Fluid resuscitation 19 (7.1) 4 (6.6) 26 (14.1) 9 (15.5)
Vasopressors 2 (0.8) 0 12 (6.5) 5 (8.6)
Invasive procedures 0 1 (1.6) 3 (1.6) 0
Isolation required 24 (9.0) 3 (4.9) 17 (9.2) 7 (12.1)
Mechanical ventilation required during
hospitalization
23 (8.6) 1 (1.6) 40 (21.7) 7 (12.1)
Invasive 12 (4.5) 0 22 (12.0) 5 (8.6)
Non-invasive 11 (4.1) 1 (1.6) 23 (12.5) 2 (3.4)
Parenteral nutrition 4 (1.5) 1 (1.6) 17 (9.2) 1 (1.7)
Duration of parenteral nutrition, days,
mean (SD) [median]
4.5 (1.0) [5.0] 12.0 (−) [12.0] 8.6 (5.3) [7.0] 3.0 (−) [3.0]
Acute renal failure necessitating renal
replacement therapy
1 (0.4) 0 5 (2.7) 1 (1.7)
Duration of renal failure, days, mean (SD) [median] 2.0 (−) [2.0] - 14.3 (16.0) [9.5] -
Septic shock during hospitalization 1 (0.4) 0 15 (8.2) 5 (8.6)
Mortality 2 (0.8) 0 1 (0.5) 3 (5.2)
*De-escalation of treatment to narrower-spectrum antibiotics upon patient improvement or confirmed microbiological diagnosis.
†Includes duration of all hospitalizations for patients with recurrences.
‡Does not include duration of all hospitalizations for patients with recurrences.
§Refers to patients hospitalized again (due to CAP) after initial discharge.
ICU = intensive care unit; SD = standard deviation.
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http://respiratory-research.com/content/15/1/6of the FOCUS comparative efficacy and safety trials of
IV ceftaroline fosamil for the treatment of CAP [25], an
advantage was seen versus the comparator ceftriaxone
in response rates at Day 4 after initiation of treatment,
using IDSA/ATS guidelines [5] for clinical stability.
In summary, this retrospective analysis of the data
obtained in the observational REACH study of patients
hospitalized with CAP, and with TCS assessment using
Halm’s criteria, emphasizes the importance of an early
response to treatment in terms of reduced morbidity
and corresponding hospital resource use.Consent
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